Smith+Nephew launches new EVOS™ WRIST Plating System; an evolutionary treatment option for both simple and complex wrist fractures
LONDON, Sept. 5, 2019 /PRNewswire/ — Smith+Nephew (LSE: SN,NYSE: SNN), the global medical technology business, today announced the launch of its EVOS WRIST Plating System at the American Society for Surgery of the Hand (ASSH) Annual Meeting in Las Vegas, Nevada.
EVOS WRIST is an ultra-versatile plating system set that gives surgeons a choice of approach, material, and locking technology to perform simple and complex wrist fracture procedures exactly the way they want to meet the specific needs of their patients.
“EVOS WRIST is a versatile, all-encompassing system with options for volar, dorsal, and forearm plating,” said Dr. Louis W. Catalano of NYU Langone Health and the Roosevelt Hand-Shoulder Center-OrthoManhattan. “Different fractures have different needs, and what sets the EVOS WRIST plating system apart is the unique flexibility it provides me to choose the best option for my patient.”
EVOS WRIST offers both stainless steel and titanium volar plate options, dorsal plates, and forearm specific plates. Stainless volar plates utilize variable-angle locking technology to allow more freedom in screw placement, as well as fixed-angle locking technology in longer plates for extra-articular fractures. Titanium options for fragment specific plates include distal ulna, intermediate column, radial column, and dorsal buttress plates.
“We are excited about EVOS WRIST for what it offers our customers – an expansive plating portfolio that’s easy to use while allowing for thoughtful consideration of all fracture types and patterns for the wrist,” said Craig Gaffin, Vice President and General Manager for Trauma and Extremities at Smith+Nephew. “It offers enhanced versatility on the standard of care for wrist fractures and rounds out our diverse portfolio of forearm/wrist/hand solutions – making it one of the most comprehensive in the market.”
EVOS WRIST is available in the US, Europe and several other global markets and complements Smith+Nephew’s comprehensive portfolio of plate and screw systems including EVOS™ SMALL, EVOS™ MINI and VLP MINI-MOD™.
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business that exists to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 16,000+ employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Advanced Wound Management and Sports Medicine & ENT. Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $4.9 billion in 2018. Smith+Nephew is a constituent of the FTSE100 (LSE:SN,NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on Twitter, LinkedIn, Instagram or Facebook.
Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as “aim”, “plan”, “intend”, “anticipate”, “well-placed”, “believe”, “estimate”, “expect”, “target”, “consider” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew’s most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew’s expectations.
™ Trademark of Smith+Nephew. Certain marks registered US Patent and Trademark Office.
SOURCE Smith & Nephew
